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Objective: A review of findings and results after standard resection for 
carcinoma of the esophagus and cardia without neoadjuvant therapy was done 
to provide a basis for comparison with current reports of radical resection and 
neoadjuvant therapy. Methods: A 24-year experience on one surgical service 
with 454 operations for carcinoma of the esophagus and cardia was reviewed. 
A comparison of findings and results in three consecutive 8-year intervals was 
analyzed, and new staging criteria were developed and compared with those 
currently favored by the American Joint Committee on Cancer. Results: From 
January 1, 1970, to January 1, 1994, 454 patients with carcinoma of the 
esophagus or cardia underwent operation, of whom 408 (90%) had esophago- 
gastrectomy with a 30-day mortality rate of 2.5% and an additional hospital 
mortality rate of 1.2%. Of the 121 complications (30.7%), 71 (18%) were major 
and 50 (12.7%) were minor. Cardiovascular complications predominated. The 
overall 5-year survival was 24.7%, with a 33.7% survival after complete 
resections in the most recent interval under study. Palliation of dysphagia was 
achieved in nearly 80% of patients who survived the operation. During the 
three intervals under review , resectability, mortality, and complication rates 
remained constant. The percentages of left thoracotomies and transhiatal 
resections increased, andthere was a decrease in thoracoabdominal incisions. 
The percentages of patients with Barrett's esophagus and stage 0 and I tumors 
increased. The percentage ofcomplete resections (R0) increased, whereas that 
for resections with residual microscopic tumor (R1) decreased, and there was 
no change in the percentage of patients with residual gross tumor after 
resection (R2). Modified WNM staging criteria are proposed that provide 
better prognostic stratification of the disease than those currently favored by 
The American Joint Committee on Cancer. Conclusions: Standard esophago- 
gastrectomy is applicable in 90% of patients with operable carcinoma of the 
esophagus or cardia, with consistently ow mortality and morbidity rates and 
satisfactory palliation of dysphagia. The 5-year survival (24.7% overall) 
remains uboptimal, but the current figure for complete resections (33.7%) 
is encouraging. There is a need for revision of the current American Joint 
Committee on Cancer staging criteria. (J Thorac Cardiovasc Surg 1997; 
113:836-48) 
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extent of the resection, as in the "en bloc" technique, 1 
or by the use of neoadjuvant therapy are currently 
being pursued aggressively. Enthusiasm for these new 
approaches prompted us to review our experience with 
standard techniques of resection, without neoadjuvant 
therapy, performed by one surgical team in an effort to 
provide a basis for comparison with the results of other 
approaches. By comparing the findings and clinical 
results in three separate consecutive 8-year intervals, 
we have attempted to determine the changes that may 
have occurred during the 24 years of the study. In so 
doing, we encountered limitations with the current 
staging criteria outlined in the Manual for Staging of 
Cancer, 2 prepared by the American Joint Committee 
on Cancer (AJCC), and have developed new staging 
criteria that provide better prognostic stratification by 
stage of disease. 
Patients and methods 
From January 1, 1970, to January 1, 1994, 454 patients 
with carcinoma of the esophagus or cardia underwent 
operation, of whom 408 (90%) had an esophagogastrec- 
tomy. Carcinomas of the cardia were included because the 
surgical approach to such lesions is similar to that for 
carcinomas of the lower esophagus. A recent comparison 
of staging criteria for esophageal and stomach cancer 
showed no difference in the staging results) Furthermore, 
current studies suggest hat up to 50% of carcinomas of 
the cardia may arise from tongues or short segments of 
Barrett's esophagus and thus have their origin from the 
esophagus rather than from gastric mueosa. 4-6 Although it 
is difficult to determine precisely the limits of the cardia, 
we continue to adhere to our original definition, 7 which 
describes a carcinoma of the cardia as one arising in the 
upper part O f the stomach and involving the esophagogas- 
tric junction and part of the lower thoracic esophagus. 
Carcinomas arising in the gastric corpus and diffuse 
carcinomas of the linitis plastica variety are excluded, even 
though they may involve the esophagogastric junction. 
Six of the 454 patients had esophageal achalasia, a 
known precursor of squamous cell carcinoma of the 
esophagus, s Only 24 patients had neoadjuvant therapy in 
the form of either radiotherapy or chemotherapy alone or 
a combination thereof: Only three of these patients lived 
5 or more years after operation. Most of these patients 
came to us after the development of recurrent dysphagia 
after failure of what had initially been undertaken as 
definitive therapy for the disease. Follow-up information 
after discharge from the hospital was based either on 
direct examination or the response to letters or telephone 
calls to the patient or the patient's relatives or physician. 
The 24-year period of the study was divided into three 
separate 8--year intervals to permit a comparison of the 
incidence of several variables (see later section) in each of 
the three periods. 
Survival was calculated by the product limit method of 
Kaplan and Meier? Tarone-Ware 1°analysis was used to 
determine the significance of survival distributions among 
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Fig. 1. Location of the tumor in 454 patients seen be- 
tween 1970 and 1994 with carcinoma of the esophagus or 
cardia. 
groups. Contingency tables were analyzed with the use of 
Miettinen's modification of Fisher's exact est ~ ~ or X 2 test 
where appropriate. Probabilities are two-tailed, with p < 
0.05 regarded as statistically significant. 
Pathology. The locations of the 454 tumors are illus- 
trated in Fig. 1:213 (47%) involved the esophagogastric 
junction, 103 (23%) the lower thoracic esophagus, 128 
(28%) the upper thoracic esophagus, and 10 (2%) the 
cervical esophagus. Of these tumors, 303 were adenocar- 
cinomas, with 208 of these being carcinomas of the cardia 
whereas 94 arose in Barrett's esophagus. Only one pri- 
mary adenocarcinoma of the thoracic esophagus was 
found. Squamous cell carcinoma was the next most com- 
mon tumor and was present in 139 patients. Twelve 
miscellaneous malignant tumors included five adenoacan- 
thomas, two small cell carcinomas, two histiocytic lympho- 
mas, two mucoepidermoid carcinomas, and one carcino- 
sarcoma. Postresection staging according to the criteria of 
the AJCC, as published in the fourth edition of the 
Manual for Staging of Cancer, 2revealed that 16 patients 
had stage 0, 22 had stage I, 80 had stage IIA, 39 had stage 
IIb, 218 had stage III, and 33 had stage IV disease (Table 
I). Patients with stage IV disease had one or more small 
metastatic deposits at operation, undetected before oper- 
ation, and underwent palliative resection for relief of 
dysphagia. 
Surgical technique. Our surgical technique for the 
management of carcinoma of the esophagus and eardia 
has been described in detail elsewhere 12, 13 and, for the 
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Table I. Histologic type of tumors and stage of the 
resected specimens 
No. 
Adenocarcinoma 303 
Cardia 208 
Barrett's esophagus 94 
Esophageal adenocarcinoma 1 
Squamous cell carcinoma 139 
Miscellaneous 12 
Adenoacanthoma 5 
Small cell carcinoma 2 
Histiocytic lymphoma 2 
Mucoepidermoid carcinoma 2 
Carcinosarcoma 1 
Total 454 
Stage 
0 16 
I 22 
IIA 80 
IIB 39 
III 218 
IV 33 
Table II. Causes of hospital mortality after 
esophagogastrectomy for carcinoma of the esophagus 
and cardia in 408 patients 
No. of 
Cause patients 
Cardiovascular 7 
Myocardial infarction 3 
Pulmonary embolus 2 
Mesenteric artery thrombosis 1 
Cardiac arrest 1 
Respiratory 
Pneumonia 1 
Respiratory failure 1 
Empyema 1 
Gastrointestinal tract 
Gastric infarction 1 
Miscellaneous 
Hepatorenal failure 2 
Thoracic duct fistula 1 
Hemorrhage 1 
Total 15 (3.7%) 
most part, was dependent on the location of the lesion. 14 
Thus for tumors of the distal esophagus and cardia, a left 
thoracotomy through the bed of the nonresected eighth 
rib was the most common procedure done (162). An Ivor 
Lewis approach was preferred for lesions at a higher level 
(118) and a transhiatal approach for selected patients in 
whom the computed tomographic scans suggested the 
absence of extraesophageal xtension or massive medias- 
tinal nodal involvement preferably for tumors located 
caudad to the trachea (96). This approach was particularly 
appropriate for patients with adenocarcinoma in Barrett's 
esophagus in whom all of the benign Barrett's mucosa 
must be removed to prevent later development of a 
second carcinoma in this abnormal epithelium. A thora- 
coabdominal incision, used early in the series in only 12 
patients, is no longer favored. Miscellaneous approaches 
were used in 4 patients, and those who required colon 
interposition (16) underwent esophagectomy and a sub- 
sternal colon interposition as a second-stage procedure. 
Exclusive of the 4 miscellaneous procedures, 279 of the 
anastomoses were done within the thorax, whereas 125 
were done in the neck, 13 after a preliminary thoracic 
incision proved inadequate to remove all the involved 
tissue, thus necessitating a separate cervical incision for 
completion of the procedure. The stomach was the pre- 
ferred esophageal substitute, with the distal colon being 
used most often in the early years of the study. All of the 
anastomoses were done manually with an inner layer of 
running catgut and an outer layer of interrupted silk or 
polyglactin 910 (Vicryl) sutures. 
Results 
Operative results. Ten patients (2.5%) died 
within 30 days of operation and an additional five 
patients (1.2%) were not able to leave the hospital 
and died later, for an overall mortality rate of 3.7%. 
The causes of death are listed in Table II: the most 
common causes were cardiovascular in nature, three 
patients dying of myocardial infarction, two of a 
pulmonary embolus, one of mesenteric artery 
thrombosis, and one of cardiac arrest during at- 
tempted computed tomographic-guided needle as- 
piration of a posterior mediastinal abscess. Three 
patients died of respiratory problems, including 
pneumonia, respiratory failure, and thoracic empy- 
ema (one each). Another died after excision of an 
area of infarcted stomach. Two patients died of 
hepatorenal failure. Another patient died of unrec- 
ognized hemorrhage the night after a transhiatal 
resection, and another died of a persistent thoracic 
duct leak, despite multiple surgical attempts to 
control the leakage. 
We recorded 121 complications (30.7%) in 110 
patients: 71 (18%) were major in that they pro- 
longed the hospitalization time and 50 (12.7%) were 
considered minor in that they did not do so. Because 
several patients had more than one complication, a 
total of 27.9% had complications. The major and 
minor complications according to general categories 
are listed in Table III. Anastomotic leakage pre- 
dominated among the major complications. Of the 
three intrathoracic leaks, one was successfully resu- 
tured, another was a contained leak successfully 
managed conservatively, and the third necessitated 
open drainage, and this patient eventually died of a 
pulmonary embolus. The cervical anastomotic leaks, 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 5 
Ellis et aL 839 
U3 
1 O0 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
I I I I I I I I I 
95% Confidence Interval N 
"~/ / /  . . . .  24.7%1~(n=66) 
. . . . . .  / / / . / / ~ ~  
I I I I [ I I I 
0 1 2 3 4 5 6 7 8 9 10 
YEARS 
Fig. 2. Adjusted actuarial survival for all patients who survived esophagogastrectomy exclusive of 
noncancer deaths, n, Number of patients remaining at risk. 
Table III. Complications in 393 survivors of esophagogastrectomy for carcinoma of the esophagus and cardia 
Major No. Minor No. 
Anastomotic leak 25 Arrhythmia 23 
Cervical 22 Respiratory 18 
Thoracic 3 Wound infection 4 
Gastrointestinal tr ct 14 Urinary tract infection 4 
Respiratory 8 Phlebitis 1 
Recurrent erve injury 5 
Subphrenic abscess 5 
Cardiovascular 4 
Chylothorax 3 
Diaphragmatic hernia 2 
Miscellaneous 5 
Total 71 (18.0%) 50 (12.7%) 
with one exception, healed spontaneously within a 
few days to 2 weeks by discontinuation of oral 
feedings and initiation of antibiotic therapy and 
hyperalimentation. One patient required surgical 
closure of the fistula. Gastrointestinal tract compli- 
cations comprised the next most common major 
complication, and these usually involved outlet ob- 
struction of the stomach. Six of these complications 
necessitated operation. Three patients needed pylo- 
roplasty. Two patients with obstruction at the level 
of the hiatus required surgical relief. One patient 
with torsion of the stomach also required surgical 
correction. The other four patients had prolonged 
gastric stasis, which eventually resolved under con- 
servative management. Other surgical corrections 
necessitated by gastrointestinal tract complications 
were cholecystectomy for acute cholecystitis (1), 
resection of the right colon because of infarction (1), 
surgical relief of small bowel obstruction (1), and 
closure of a gastric leak from the staple line of the 
lesser gastric curvature closure (1). Seven of the 
eight respiratory complications were the result of 
pneumonia, which responded to appropriate antibi- 
otics. One patient with thoracic empyema was 
treated successfully by tube drainage. 
Among the five patients who had recurrent nerve 
injury, the nerve was purposely sacrificed because of 
involvement by the tumor in one patient. Another 
patient is still alive and has hoarseness and presum- 
ably permanent nerve damage. Two others died of 
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Fig. 3. Adjusted actuarial survival for patients with R0 (no residual tumor), R1 (microscopic residual 
tumor), and R2 (obvious residual tumor) conditions after resection, n, Number of patients remaining at 
risk. 
metastatic disease within 2.5 and 3 years, and the 
status of the vocal cord function was unknown. A 
fifth patient is still alive and recovered vocal cord 
function a few months after operation. Of the five 
patients with subphrenic abscesses, two required 
open drainage, whereas the other three w re treated 
successfully by catheter drainage. The cardiovascu- 
lar complications included two strokes, one myocar- 
dial infarction, and one case of congestive heart 
failure. In three patients, a postoperative chylotho- 
rax developed that required surgical ligation of the 
thoracic duct, and two patients had postoperative 
herniation of the stomach through the widened 
hiatus, which necessiated surgical reduction. Three 
of the miscellaneous complications necessitated 
splenectomy after operative injury to the spleen. 
One patient died of multiple system failure, and 
another patient died of renal failure. 
The majority of minor complications were related 
to cardiac arrhythmias (23), which were controlled 
for the most part by antiarrhythmic medications. 
Respiratory complications (18) included excessive 
retained secretions necessitating bronchoscopy. 
Wound infections (4), urinary tract infections (4), 
and phlebitis (1) accounted for the rest of the minor 
complications. 
Because palliation of dysphagia s one of the main 
goals of esophagogastrectomy, information on this 
point is important. Worthwhile information was 
available for 356 patients, 277 (78%) of whom had 
partial or complete relief of swallowing difficulties. 
Because many patients died at home without a 
postmortem examination, whether stenosis of the 
anastomotic site was benign or malignant is not 
known with assurance. There were, however, 32 
known anastomotic recurrences among the 393 sur- 
vivors of resection (8%). 
Survival. Actuarial survival curves for all pa- 
tients, adjusted for hospital and noncancer deaths, 
are depicted in Figs. 2 through 5. The overall 5-year 
survival was 24.7%, with a median survival of 18 
months (Fig. 2). In Fig. 3, survival curves related to 
the completeness of the resection are depicted. 
Patients who had a complete resection (R0) had a 
29.2% 5-year survival, with a median survival of 21.5 
months. No patient with residual microscopic evi- 
dence of tumor (R1) survived for 5 years, and the 
median survival for these patients was 102/3 months. 
Patients with gross evidence of residual tumor after 
resection (R2) also did not survive for 5 years. The 
median survival in this latter group was 7.5 months. 
The survival curves according to the histologic type 
of the resected tumor are shown in Fig. 4. The 
5-year survival of patients with Barrett's esophagus 
was 32.6%, with a median survival of 232/3 months. 
Patients with adenocarcinoma of the cardia had a 
25.3% 5-year survival, with a median survival of 18 
months, whereas patients with squamous cell carci- 
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Fig. 4. Adjusted actuarial survival curves according to histologic types, n, Number of patients remaining 
at risk; CA, carcinoma; Adeno, adenocarcinoma; SCE, squamous cell carcinoma. 
noma had a 20.7% 5-year survival, also with a 
median survival of 18 months. These survival data 
were not significantly different statistically. The 
stage of the tumor, however, as illustrated in Fig. 5, 
had a profound impact on survival. Of patients with 
stage 0 tumors, 100% survived for 5 years, with a 
median survival of 20.5 years; 78.9% of patients with 
stage I disease survived 5 years, with a median 
survival of 162/3 years; 37.9% of patients with stage 
IIA disease survived 5 years, with a median survival 
of 21/2 years; 27.3% of patients with stage liB lesions 
survived 5 years, with a median survival of 12/3 years; 
and 13.7% of patients with stage III lesions survived 
5 years, with a median survival of 11/4 years. No 
patient with stage IV disease survived for 5 years, 
and the median survival in this group was only 6 
months. 
Compar i son  of  f ind ings  and  resul ts  in three 
consecuth~e e ight -year  intervals .  In an effort o iden- 
tify measurable trends either in the nature of the 
disease or in its treatment over the 24 years of the 
study that might be helpful in the treatment of 
patients with carcinoma of the esophagus and car- 
dia, we divided our data into three consecutive 
8-year intervals a depicted in Table IV. A number 
of variables were analyzed statistically, and the 
findings can be summarized briefly as follows: the 
number of patients in each 8-year interval increased 
during the 24 years of the study. In the first period 
(1970 to 1978), there were 64 patients; from 1978 to 
1986, 187 patients; and between 1986 and 1994, 203 
patients. Resectability, hospital mortality, and post- 
operative complication rates remained constant. 
The percentages of left thoracic and transhiatal 
surgical approaches increased (p = 0.0177 and p < 
0.0001, respectively), and there was a decline in 
thoracoabdominal incisions (p < 0.0001). The per- 
centage of patients with adenocarcinoma in Bar- 
rett's esophagus increased (p = 0.0001) as did the 
percentage of stage 0 tumors (p = 0.0078). Al- 
though there was no change in the percentage of 
stage I tumors, the combined group of patients 
with stage 0 and those with stage I tumors exhib- 
ited a pronounced increase at the p = 0.0177 
level. The percentage of patients who had R0 
resections increased (p = 0.0455), whereas the 
percentage of R1 resections decreased (p = 0.015) 
and there was no change in the percentage of R2 
resections. The overall 5-year survival was higher 
during the most recent interval than that during 
the previous one (28.8% vs 20.3%), but the overall 
trend of mortality rates was not significantly dif- 
ferent statistically. The percentage of patients 
who had partial or complete relief of dysphagia 
decreased slightly in the most recent interval 
compared with that in the earliest 8-year period of 
the study. 
Proposa l  for improved s tag ing  cr iter ia.  In a pre- 
vious publication, 3 we questioned the validity of the 
staging criteria proposed in the revised Manual for 
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Fig. 5. Adjusted actuarial survival curves by stage using AJCC criteria, n, Number of patients remaining 
at risk. 
Cancer Staging for prognostic stratification of cases 
of carcinoma of the esophagus and cardia because it
provided no better stratification than the earlier 
edition. 15 This prompted us to propose a revised 
staging system based on a modification of the WNM 
system of Skinner and associates. 16 We expanded 
our patient base by including all of the patients 
presented in this report and compared the AJCC 
staging criteria with those of the modified WNM 
version previously presented by us. The only change 
in our original proposal is the transfer of the W2 
(T3, T4) N1 condition from stage II to stage III (Fig. 
6). The comparison is presented in Table V. With 
use of the new staging criteria, not only is the 
number of patients more evenly divided among the 
four stages but also the comparison between stages 
of 5-year survivals is highly significant statistically, 
with almost a 50% reduction in survival rates for 
each increasing stage. With the current AJCC crite- 
ria for staging, only two of the comparative analyses 
between stages are significantly different, and the 
remaining three show no statistically significant dif- 
ference in the 5-year survivals. 
The major difference in the staging criteria of the 
proposed new system is the recognition that the 
number of lymph nodes involved has a profound 
effect on prognosis: NO (no nodes involved), N1 (1 to 
4 nodes involved), and N2 (5 or more nodes in- 
volved). The T categories and their corresponding 
W numbers are TO, Tis, and T1 = W0; T2 = Wl; and 
T3 and T4 = W2. 
Discuss ion  
The experience with standard resection for carci- 
noma of the esophagus and cardia that we have 
reported herein is similar to that of other recent 
reports from major centers in the United States, 
with hospital mortality rates of 5% or less and 
postoperative complication rates of about 30%. 1719 
Higher complication rates, from 60% to 70%, how- 
ever, have been reported both from this country and 
from Europe. 2°-22 Respiratory complications and 
anastomotic leaks, which in earlier years predomi- 
nated, 23 are no longer the major complications of 
esophagogastrectomy in our hands; rather, cardio- 
vascular complications predominate. Other reports, 
however, still indicate the predominance of respira- 
tory problems after operation. 24-26 Although the 
number of cervical anastomotic leaks appears high, 
22 (17.6%) of 125, this is not out of line with the 
10% to 30% incidence of cervical anastomotic leaks 
reported in the literatureY' 2s It should be empha- 
sized that none of our cervical leaks proved life 
threatening and all but one healed with conserva- 
tive management. Our resectability rate of 90% is 
also higher than that usually reported, which 
could easily be a reflection of patient population 
differences among hospitals. In contrast to an- 
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Table IV. Comparison of findings and results in three separate &year intervals 
1970-1978 (64 patients) 1978-1986 (187 patiens) 1986-1994 (203 patients) 
No. of patients % No. of patients % No. of patients % p Value 
Resectability 54/64 84.3 168/187 89.8 186/203 91.6 NS 
Mortality 3/54 5.6 5/168 3.0 7/186 3.7 NS 
30-day 2/54 3.7 2/168 1.2 6/186 3.2 NS 
Hospital 1/54 1.9 3/168 1.8 1/186 0.5 NS 
Complications 20/51 39.2 40/163 24.5 61/179 34.0 NS 
Major 10/51 19.6 22/163 13.5 39/179 21.8 NS 
Minor 10/51 19.6 18/163 11.0 22/179 12.3 NS 
Operations 
Left thoracic 16/54 29.6 80/168 47.6 66/186 35.5 0.0177 
Ivor Lewis 22/54 40.7 47/168 27.9 49/186 26.3 NS 
TranshiaLal 0/54 0 31/168 18.5 65/186 34.9 <0.0001 
Thoracoabdominal 10/54 18.5 1/168 0.6 1/186 0.5 <0.0001 
Colon 4/54 7.5 8/168 4.8 4/186 2.3 NS 
Miscellaneous 2/54 3.7 1/168 0.6 1/186 0.5 NS 
Pathologic findings 
Adenocarcinoma of cardia 32/64 50.0 91/187 48.7 81/203 40.0 NS 
Squamous cell carcinoma 25/64 39.0 58/187 31.0 62/203 30.5 NS 
of esophagus 
Adenocarcinoma of Bar- 4/64 6.3 31/187 16.6 58/203 28.5 0.0001 
rett's esophagus 
Miscellaneous 3/64 4.7 7/187 3.7 2/203 1.0 NS 
R0 39/54 72.2 144/168 85.7 159/186 85.5 0.0455 
R1 6/54 11.1 3/168 1.8 10/186 54.4 0.0150 
R2 9/54 16.7 21/168 12.5 17/186 9.1 NS 
Stage 
0 1/54 1.9 2/168 1.2 14/186 7.5 0.0078 
I 1/54 1.9 6/168 3.6 14/186 7.5 NS 
IIA 11/54 20.3 38/168 22.6 27/186 14.5 NS 
IIB 10/54 18.5 18/168 10.7 16/186 8.6 NS 
III 24/54 44.4 93/168 55.4 100/186 53.8 NS 
IV 7/54 13.0 11/168 6.5 15/186 8.1 NS 
5-Year survival 27.2 20.3 28.8 NS 
Palliation 44/50 88.0 108/151 71.5 125/155 80.6 0.0264 
NS, Not significant; RO, complete resection; R1, residual microscopic evidence of tumor after resection; R2, obvious residual tumor after resection. 
other report that compared findings in different 
consecutive time framesy our mortality, resect- 
ability, and complication rates have remained 
stable, presumably because our earlier figures 
were low in terms of mortality and complications 
and relatively high in terms of resectability. How- 
ever, we too noted an increasing number of cases 
of Barrett's carcinoma and, presumably as a result 
of surveillance programs for patients with benign 
Barrett's disease, an increased number of patients 
in the early stages of the disease in the most 
recent interval studied. Although it was not sur- 
prising that the percentage of patients undergoing 
transhiatal resections increased and the percent- 
age of those undergong thoracoabdominal ap- 
proaches decreased, the increase in left thoracotomy 
approaches was not anticipated in view of the wide- 
spread enthusiasm for the Ivor Lewis approach in 
this country. 
The 5-year survival of 28.8% (33.7% for patients 
having R0 resections) in the most recent 8-year 
interval is higher than that most commonly reported 
in the Western world but lower than that reported 
from Japan, particularly in series in which a "three- 
field" resection was done. 29' 30 Although these dif- 
ferences may be stage related, rather than the result 
of the extent of resection, they raise the question of 
whether standard resection techniques provide the 
patient with the best chance for cure. More radical 
resection would seem unlikely to benefit patients 
with early-stage disease in view of the excellent 
survival being reported here after standard resection 
in such cases. Comparisons with reports from the 
United States by those using radical resection are 
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Table V. Comparison of two staging systems 
Stage 
AJCC Modified WNM criteria 
No. of 5-yr No. of 5-yr 
patients survival (%) p Value Stage patients survival (%) p Value 
0 16 100 
I 22 78.9 
IIA 80 37.9 
IIB 39 27.3 
III 218 13.7 
IV 33 0 
0 T0, is, 1 (W0) NO 39 88.2 
NS } 0.0002 
T1 (W0) N1 59 50.3 / 
0.0021 T2 (W1) NO 1 0.0005 
IX T2 (W1) N1 95 22.5 
NS } 0.0213 
T3, 4 (W2) NO 
NS 
III T3, 4 (W2) N1 182 10.7 / 
<0.0001 Any T N2 / <0.0001 
IV M1 33 0 
NS, Not significant. 
hard to interpret because of the highly selective use 
of these procedures. 3t One report, that from the 
service of the originator of the "en bloc" proce- 
dure, 32 is worth analyzing. It involved 251 patients of 
whom only 111 (44.2%) had the radical procedure, 
with an 11% hospital mortality rate and an overall 
5-yea r survival of 19%. When we translated our data 
into their WNM criteria, their 5-year survival com- 
pared with ours is as follows: Wl N0 (55% vs 50%), 
W1 N1 (29% vs 27%), W2 NO (15% vs 22%), and 
W1/W2 N2 (8% vs 11%). A comparison of these two 
series, although admittedly based on shaky grounds, 
if anything, favors standard resection over the "en 
bloc" technique. 
Equally as important as survival is the ability of 
the operation to provide palliation of dysphagia. 
This was achieved in nearly 80% of the patients for 
whom information was available, which is a figure 
comparable to that in our earlier reported experi- 
enceY' 34 Some failures of palliation were the result 
of anastomotic recurrences (8%), an identical figure 
to that reported from Hong Kong where experience 
with esophagogastrectomy for carcinoma is far 
greater than in the Western world. 35 Anastomotic 
recurrences might have been minimized by a more 
radical esophagectomy, but because the vast major- 
ity of the patients have distant metastatic disease at 
the time local recurrence is diagnosed, it is debat- 
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able whether the increased morbidity of such a 
procedure is justified. 
The question of the role of neoadjuvant therapy 
for carcinoma of the esophagus and cardia remains 
unsettled, although the results of multiple phase II 
trials have been reported. In general, they show that 
up to 30% of patients exhibit a complete histologic 
response to chemoradiation at the expense of con- 
siderable toxicity in terms of myelosuppression) s 
Survival of patients with a complete response is 
increased over that of historical controls. Although 
few phase III studies have been reported, the pre- 
liminary results of the University of Michigan's 
study involving 100 patients are discouraging. 37The 
median survival was 18 months in both arms of the 
study, and the 2-year survival was 36% for patients 
having operation alone and 41% for patients under- 
going combined therapy. Neoadjuvant therapy for 
the treatment of carcinoma of the esophagus and 
cardia remains investigational. Although continued 
prospective randomized studies in centers partici- 
pating in research protocols are justified, operation 
remains the standard treatment for this disease. 
The importance of staging in predicting the long- 
term survival of patients after resection for carci- 
noma of the esophagus and cardia is reemphasized 
by the findings we report herein. Unfortunately, the 
current staging criteria as proposed by the AJCC fail 
to prognostically stratify the disease conditions ad- 
equately. The modified WNM staging criteria that 
we are proposing provide improved prognostic strat- 
ification, as clearly depicted in Table V. Missing 
from this proposal is the recent recommendation f 
the TNM committee of the Union Internationale 
Contre le Cancer (UICC) that stage T1 be divided 
into Tla (tumor invades lamina propria) and Tlb 
(tumor invades submucosa)) 8 Sabik and associ- 
ates 39 reported that Tis and intramucosal carcino- 
mas are associated with a significantly better prog- 
nosis than those with submucosal involvement. We 
are currently reviewing our data to see whether they 
confirm these observations. Also proposed by the 
TNM committee is a change in the N classification, 
with three categories of involved nodes, depending 
on the number. Because the 5-year survivals associ- 
ated with two of these categories were identical 
(0%) in the committee's report, the N1, N2 proposal 
of ours is simpler and just as accurate. The commit- 
tee has also altered the M Classification into two 
separate categories, depending on the location of 
the nodal metastases. However, we have always 
considered metastases from lower thoracic esopha- 
geal carcinomas to the celiac nodes as N1 or N2 
rather than M1 disease, as have Ide and associates 4°
from Japan. Much work remains to be done if 
universally acceptable staging criteria for carcinoma 
of the esophagus and cardia that provide satisfactory 
prognostic stratification of disease conditions are to 
be achieved. 
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Discussion 
Dr. John R. Benfield (Sacramento, Calif.). This thought- 
ful report from the dean of United States surgery is 
remarkably successful in meeting its goal. The authors 
have indeed been successful in providing us with a base- 
line as to what one can and cannot expect from resection 
as the treatment of esophageal cancer. I would like to 
highlight a number of points. 
Achalasia is indeed associated with esophageal cancer, 
but in the authors' experience the coincidence ofachalasia 
and esophageal cancer was low, about 2%. Barrett's 
dysplasia with esophageal cancer is common, greater than 
20%, and this coincidence continues to increase for 
reasons that we do not fully understand. 
In skilled experienced hands, the incidence of intratho- 
racic anastomotic disruption is now remarkably small. 
However, the patients who need esophageal resection to 
treat cancer are so ill that a postoperative complication 
rate, at least in the United States, of about 30% is about 
the best one can expect. The bright side includes amedian 
survival greater than 16 years in patients with stage 0 
cancers. In stark contrast are the median survivals of 6 
months to 21/2 years whenever the cancers have shown any 
evidence of spread into lymphatics or when there is 
microscopic evidence of postresection residual cancer. 
This finding suggests that the principles of staging an 
esophageal cancer are no different from the principles of 
staging in cancer of the lung or cancer of the breast or 
cancer of the colon. When cure cannot be achieved it is 
abundantly clear that complete resection gives about 80% 
of patients the best available palliation. These are the 
standards that need to be exceeded if induction or neo- 
adjuvant therapy is to have a lasting therapeutic role. 
We participated in a multiinstitutional cooperative in- 
tergroup-administered clinical trial by the Radiation On- 
cology Group wherein induction therapy before resection 
is being compared with proceeding directly to esopha- 
gectomy. The results are not yet available, but it will not 
surprise me if induction or neoadjuvant therapy fails to be 
of lasting benefit. In a preliminary report given by Dr. 
Robert Ginsburg to the General Thoracic Surgical Club 
last March, it was noteworthy that the incidence of 
anastomotic disruptions and complications has been strik- 
ingly low; that is, in the range of today's report by Dr. 
Ellis. From this, one can conclude that thoracic surgeons 
who do a significant number of esophagectomies can 
accomplish them safely even in patients in debilitated 
condition: It would be of interest to compare results like 
those of Dr. Ellis and the intergroup thoracic surgeons 
with the results of surgeons who occasionally perform 
esophageal operations. I suspect hat the findings would 
make a compelling argument in favor of restricting esoph- 
ageal surgical practice to centers of excellence, and I hope 
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that there will be an opportunity to evaluate this hypoth- 
esis. 
One of Dr. Ellis' major points is his group's proposal for 
refined, precise staging nomenclature. I certainly agree 
with the idea that staging is crucially important and, 
therefore, on a daily basis I insist that my residents and 
students always include TNM and staging descriptions 
when discussing the cases of patients with cancer. Dr. 
Ellis' specific proposal for modification of nomenclature is 
worthy and thoughtful, but it really cannot be effective 
until there is another international agreement as to the 
nomenclature that will be used. I support proposals for 
change such as the one we have heard today, but I 
emphasize that consensus and agreement are required. 
The generally accepted standards for staging nomencla- 
ture should not be abandoned until there is something 
generally accepted to take its place. 
In my own practice, despite routine pyloroplasty or 
pyloromyotomy, transient and sometimes prolonged post- 
operative gastric stasis remains a problem. Clearly a 
pyloroplasty is not always a sufficient solution and there- 
fore there are excellent esophageal surgeons in the United 
Kingdom and elsewhere who do not routinely use pyloro- 
plasty or pyloromyotomy. Thus I close by asking Dr. Ellis 
to enlighten us as to how best to avoid and to treat gastric 
stasis in conjunction with esophagectomies. 
Dr. Ellis. I would like to first make a comment or two 
about some of the things that Dr. Benfield has said. I 
agree that, in all likelihood, early diagnosis is going to be 
the only way we can improve long-term postresection 
survival, because the results of superradical procedures 
and neoadjuvant therapy have not been encouraging. 
Preliminary optimistic results of phase II neoadjuvant 
studies were not supported by the initial results of a 
prospective randomized study from the University of 
Michigan, which was published only in abstract form. The 
median survival was 18 months in both arms of that study 
and the 2-year survival was 36% for patients undergoing 
operation alone and 41% for those undergoing combined 
therapy. Although the data at 5 years will be interesting, it 
is doubtful that there will be any statistically evident advan- 
tage of the neoadjuvant approach over standard approaches. 
The comments regarding the results of operation by 
surgeons who occasionally perform esophageal operations 
are pertinent, and, in fact, Dr. Matthews from the United 
Kingdom has made such a comparison and found a major 
difference in hospital mortality rates for the "occasional" 
surgeon as compared with the rates for those who perform 
many esophagectomies. 
Gastric emptying is always a potential postoperative 
problem after bilateral vagotomy, and it is surprising to 
me that it is not a more common occurrence. Of the 14 
gastrointestinal tract complications of esophagogastrec- 
tomy we reported, 7 could be related to gastric stasis, and 
3 of these patients required pyloroplasties. The other 
cases resolved under conservative management. Approx- 
imately 10% of patients in whom the left thoracic ap- 
proach is used, in which a gastric drainage procedure is 
not done, will have problems with gastric emptying. It is 
my custom, however, to do a pyloromyotomy when either 
an Ivor Lewis or a transhiatal resection is done, despite 
which some patients have problems with gastric emptying. 
As Dr. Benfield indicated, the British, for the most part, 
advise against performance of a gastric drainage proce- 
dure because of the problem of bile reflux and have 
treated those patients with troublesome gastric stasis by 
per oral dilation of the pyloric sphincter muscle. However, 
the use of prokinetic drugs such as bethanechol chloride 
(Urecholine), metoclopramide hydrochloride (Reglan), 
and cisafride (Propulsid) usually controls the symptoms, 
though they may take considerable time to resolve. 
Dr. Tom R. DeMeester (Los Angeles, Calif.). I have been 
privileged to have the unique opportunity to review two 
manuscripts ummarizing the life work on esophageal 
carcinoma by two surgeons. Like Dr. Akiyama, Dr. Ellis 
has invested a major portion of his life to studying this 
disease. Their two manuscripts summarize their personal 
work on the subject and reflect he commitment each has 
had to further our understanding of a disease that is slow 
to yield its secrets. The prevalence of esophageal carci- 
noma is such that it is common enough to be a menace but 
uncommon enough that a lifetime is required to under- 
stand the disease in its details. All of this may change if the 
current prevalence of adenocarcinoma of the esophagus 
and cardia continues to increase. If its rise remains on the 
current course, it will become one of Western man's most 
common cancers. 
Dr. Ellis, 65% of the patients in this series had adeno- 
carcinoma, whereas this histologic type was rarely seen by 
Dr. Akiyama. Do you have any thoughts as to why there is 
such a difference in histologic type of the tumor between 
the East and the West? 
Dr. Ellis. The Japanese rarely have gastroesophageal 
reflux disease so they do not get Barrett's esophagus and 
hence they do not get adenocarcinoma as often as occurs 
in the Western world. 
Dr. DeMeester. Do you have any reason why the 
Japanese do not get reflux? 
Dr. Ellis. The Japanese are rarely as fat as are many 
Americans. Other than that, I have no real explanation. 
Maybe Hiroshi could answer that question, but gastro- 
esophageal reflux disease is not common in Japan. 
Dr. DeMeester. Because of the opportunity afforded me 
in reviewing both manuscripts, I noticed that Dr. Ellis' 
survival for patients with seemingly similar stages of 
disease, that is, tumors that penetrate the submucosa nd 
muscular propria, is about half that of Dr. Akiyama. As a 
consequence, Dr. Ellis, are these results moving your 
group toward a more extensive resection for patients with 
an intermediate stage of disease, that is, disease beyond 
the muscularis mucosa but not advanced to the point of 
penetration into the adventitia nd involving multiple 
lymph nodes? 
Dr. Ellis. No, because Dr. Akiyama's 5-year survival 
before he began doing three-field resections was far better 
than any reported from the Western world. It makes one 
wonder whether there is a difference in the biologic 
makeup of the tumor in Japan. Also, the selection of a 
radical approach not only by Dr. Akiyama but also by Dr. 
Skinner and his group is highly selective. The most 
favorable cases are selected for the radical approach. In 
such cases, our 5-year survival is 75%. Those are the ones 
selected for total gastrectomy, whereas the ones in which 
resection is done have a much higher risk and the results 
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are similar. The same applies to Dr. Skinner's data. 
Long-term results of Skinner's "en bloc" resection are 
reported in a chapter in a textbook and involve 100 
patients, who incidentally make up only 44% of all the 
cases this group saw. The mortality- rate was 11%; ours is 
3%. Skinner's 5-year survival was 19%; ours is 24.7%. 
Dr. DeMeester. I compliment Dr. Ellis on his attempt to 
improve our staging of esophageal cancer. His modifica- 
tions have clearly separated the stages of disease to the 
point where they have prognostic significance. Further, 
because his group has focused on tumor removal and not 
on an exclusive lymph node dissection, these data provide 
an excellent baseline for what can be accomplished by 
minimal dissection. What we need is for Dr. Akiyama to 
arrange his data into Dr. Ellis' proposed staging classifi- 
cation. If this were done, I am sure we would learn more 
from the two men collectively than we have from each 
separately. I would encourage the two of them to get 
together and with use of the staging system proposed by 
Dr. Ellis publish a letter comparing the results achieved by 
an advocate for a limited dissection with those of an 
advocate for an extensive dissection. 
It is a tribute to the Society to have these two classic 
papers presented at its meeting, and I thank both Dr. 
Akiyama and Dr. Ellis for their contributions. 
Dr. Arthur Thomas (San Francisco, Calif.). We have 
noticed a similar increase in Barrett's esophagus over the 
same time frame and a question I wanted to ask is whether 
the patients in whom Barrett's esophagus malignant de- 
generation is developing are being overtreated by the 
gastroenterologist. It seems to me that referral for hiatal 
hernia repair occurs after complications have developed, 
because gastroenterologists can relieve the symptoms o 
well with the H2 blockers and it is not until after many 
years of treatment that discovery of a complication is 
made. Even the patients with Barrett's esophagus are not 
ordinarily referred and they are included in a surveillance 
program. We recently treated a patient who one year had 
negative findings for malignancy and the next year had 
positive findings, and he had one lymph node that was 
positive, which according to the findings in the current 
report would make him half as likely to survive 5 years. I
would be interested in the authors' thoughts in this area. 
Dr. Ellis. There is no question that Barrett's esophagus 
is a premalignant lesion. People with benign Barrett's 
esophagus have a 75-fold increased risk for the develop- 
ment of cancer compared with that of an age- and 
sex-adjusted population; thus anyone with Barrett's 
esophagus needs at least yearly endoscopic surveillance. 
We have determined that such an approach is cost effec- 
tive. If there is any evidence of what some call high-grade 
dysplasia, which is synonymous with in situ carcinoma, 
such patients hould have resection because a third to a 
half will have invasive cancer in the resected specimen. 
When we followed that approach, the 5-year survival of 
patients in whom cancer was detected uring surveillance 
was in the neighborhood of 60% to 70%, as compared 
with that of patients with adenocarcinoma in Barrett's 
esophagus when we first see them with cancer, in whom 
the survival is about 20% to 25%. In my opinion close 
surveillance is the answer to better long-term survival, 
because it permits resection at an early stage of the 
disease. One final word about this matter is that perfor- 
mance of an antireflux operation does not protect such 
patients from subsequent malignant ransformation of 
benign Barrett's mucosa. 
Dr. Thomas. I was thinking of patients before Barrett's 
esophagus develops. The thing that I find worrisome is the 
sampling error in patients with Barrett's esophagus, and I 
think that the risk for the patient undergoing biopsy as 
concerns the true status of the Barrett's esophagus i not 
really known. 
Dr. Ellis. Sampling errors certainly occur with conven- 
tional endoscopic techniques. The group from the Uni- 
versity of Washington has advocated taking giant biopsy 
bites at many levels, and they say that by doing so they can 
eliminate the sampling error and decrease the need for 
resection. I think the techniques that are being looked 
into now, such as the use of laser obliteration of the 
abnormal mucosa followed by antireflux maneuvers, may 
stimulate regrowth of squamous epithelium and minimize 
the chance of later malignant transformation. 
Dr. Robert Mitchell (Mountain View, Calif.). I have 
followed Dr. Ellis' work and believe that his work is the 
gold standard, with one caveat, however. I noticed that his 
group continues to do a left thoracotomy for gastroesoph- 
ageal junction cancers. I performed a few left thoracoto- 
mies in the early days in the 1970s but concluded that 
proximal margins could be a problem and thereafter have 
used the Lewis approach routinely. Previous papers from 
this group quoted an 11% anastomotic recurrence rate 
with gastroesophageal junction adenocarcinomas. I would 
consider that a rather high percentage. Would the authors 
not consider that these results might be a result of an 
anastomosis this is not proximal enough with the left 
thoracotomy as opposed to a right thoracotomy, with 
which I routinely put the anastomosis above the azygos or 
sometimes in the neck? 
Dr. Ellis. We always obtain frozen sections at the time 
of the operation, and it is true that adenocarcinomas of 
the cardia tend to spread proximally submucosally, but 
they do not have skip areas like some squamous cancers 
do. Most of the left thoracotomies were done for cancers 
of the cardia, and some of them had to be converted into 
a more extensive resection with a cervical anastomosis. It 
is difficult o do this through a left thoracotomy, but it can 
be done. In some patients we had to convert he proce- 
dure into an Ivor Lewis operation. As indicated in the 
manuscript, our local recurrence rate remains about 8% 
to 10%. Unfortunately, most of the patients have meta- 
static disease when they get the local recurrence. Whether 
the performance of a superradical procedure with its 
attendant morbidity and mortality is worthwhile just to get 
a few more centimeters of tissue when the cause of death 
is not the local recurrence but the metastatic disease 
remains debatable. 
Dr. Mitchell. At least in my experience, I would not 
think that an Ivor Lewis approach increases the mortality 
or morbidity. 
Dr. Ellis. I am referring to the superradical operations 
that some of the physicians in this room advocate. 
